| Previous Close | 2.0700 |
| Open | 2.1000 |
| Bid | 2.0800 x 0 |
| Ask | 2.1200 x 0 |
| Day's Range | 2.0800 - 2.1000 |
| 52 Week Range | 0.8000 - 3.2500 |
| Volume | 5,000 |
| Avg. Volume | 16,475 |
| Market Cap | 73.043M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3120 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Newsfile
NervGen to Present at the LifeSci Partners 10th Annual Healthcare Corporate Access Event
Vancouver, British Columbia--(Newsfile Corp. - January 5, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that Paul Brennan, President & CEO, will conduct a corporate presentation at the LifeSci Partners 10th Annual Healthcare Corporate Access Event on Wednesday, January 6, 2021 at 3:00pm Eastern Time. Investors interested can pre-register for ...
- Newsfile
NervGen Pharma Engages CRO for Phase 1 Clinical Trial
Vancouver, British Columbia--(Newsfile Corp. - December 15, 2020) - Â NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that it has engaged Novotech (Australia) Pty Limited ("Novotech"), a leading full-service contract research organization ("CRO") in Asia-Pacific, for its upcoming Phase 1 clinical trial for NVG-291. NervGen currently plans to initiate its Phase 1 ...
- Simply Wall St.
Is NervGen Pharma (CVE:NGEN) In A Good Position To Invest In Growth?
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
